bioAffinity Technologies, Inc. filed a Form 8-K on November 17, 2026, disclosing that a record number of its CyPath Lung tests were performed in October 2026, representing the highest monthly testing volume for the noninvasive lung cancer test in the company's history according to the filing.

Key Highlights

  • Record monthly volume: A record number of CyPath Lung tests were performed in October 2026, according to the filing.
  • Milestone characterization: The filing describes October 2026 as marking "the highest monthly testing volume for the Company's noninvasive lung cancer test."
  • Product identity: CyPath Lung is described in the filing as a noninvasive lung cancer test.
  • Event date: The press release disclosing the milestone was issued on November 11, 2026.
  • Registrant: bioAffinity Technologies, Inc. is incorporated in Delaware and headquartered in San Antonio, Texas.
  • Emerging growth company: The filing indicates the registrant qualifies as an emerging growth company under applicable SEC rules.

CyPath Lung Reaches Monthly Testing Record in October 2026

According to the Form 8-K filed with the SEC on November 17, 2026, bioAffinity Technologies, Inc. reported that October 2026 saw a record number of tests performed using its CyPath Lung platform. The filing states this represented "the highest monthly testing volume for the Company's noninvasive lung cancer test," as announced via a press release dated November 11, 2026, which is attached to the filing as Exhibit 99.1.

bioAffinity Technologies is a Delaware corporation with principal executive offices located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217. The company's common stock trades on the Nasdaq Capital Market under the symbol NASDAQ:BIAF, and its warrants to purchase common stock trade under the symbol BIAFW on the same exchange. The company holds emerging growth company status as defined under applicable securities regulations, as indicated on the cover page of the filing.

The 8-K was filed under Item 8.01 (Other Events) and signed by Maria Zannes, President and Chief Executive Officer, on behalf of the registrant. No specific numerical test count was disclosed within the body of the 8-K itself; the filing directs readers to the attached press release, Exhibit 99.1, for the full announcement.

What Was Disclosed

bioAffinity Technologies filed a current report disclosing that October 2026 represented the highest monthly testing volume on record for its CyPath Lung noninvasive lung cancer test, with the supporting press release incorporated as Exhibit 99.1.